Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/ekhzCfbwocfbpQgJTWIq

February 13, 2013
Sign upForwardArchiveAdvertiseRead more at SmartBrief.com
News for nuclear medicine and molecular imaging professionals
 
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.

  Top Story 
 
  • SNMMI strengthens partnership with Chinese nuclear med group
    SNMMI and the Chinese Society of Nuclear Medicine partnered last month to hold the second Sino-American Conference with the aim of advancing a global partnership for nuclear medicine and molecular imaging. The meeting, held alongside SNMMI's Mid-Winter Meeting, discussed challenges in the field, including issues with reimbursement and the push to advance training of nuclear medicine technicians in China. "They are on a very steep slope of increasing PET and PET/CT capabilities in China," said SNMMI President Frederic Fahey. SNMMI is collaborating with the International Atomic Energy Agency on continuing education resources for CSNM. The growing partnership with China is helping SNMMI grow its global program, which now involves 13 international groups. AuntMinnie.com (free registration) (2/12) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
Every patient is UNIQUE.
So why should they all receive the same PET dose? The MEDRAD™ Intego™ PET Infusion System makes personalization practical. Clinicians can administer an accurate, personalized dose for each patient from a simple touch screen. To see how the MEDRAD™ Intego™ is enabling better patient care, click here.
  Clinical News & Research 
  • Study: Biomarker model predicts advancing dementia
    A biomarker model showed utility in predicting the progression of Alzheimer's disease in patients with mild cognitive impairment, according to a study from Italy published in Neurology. Data showed all patients who had all the biomarkers evaluated saw their dementia symptoms progress, while only one patient in a group that did not have any biomarkers included in the model had symptom advancement during the study period. MedPage Today (free registration) (2/12) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  News from the Field 
  • RadSnap app allows for image consultation
    Dr. Roland Talanow, founder of nonprofit radiology group Radiolopolis, has launched an application called RadSnap. The free app, compatible with iPhones, iPads and Android devices, allows physicians to take and share a medical image with Radiolopolis-affiliated experts for consultation. The app is intended for physicians who have limited access to other clinicians for second opinions, such as those who work in remote areas. Talanow said he is collaborating with PACS companies for the integration of the RadSnap app into their systems. A desktop version is also being created. AuntMinnie.com (free registration) (2/12) LinkedInFacebookTwitterEmail this Story
  International Developments 
  • Japan loosens stability testing requirements for devices
    Japan will no longer require medtech companies to include stability testing data in order to get approval for devices after a Regulatory Task Force agreed the requirements could be eliminated in most cases. The task force is made up of representatives of the country's Ministry of Health, Labour and Welfare and the medical device industry. The move is meant to alleviate the delay in medical device approval in Japan, but some devices still require the data, including those that contain certain raw materials, biological products and radioactive material. Clinica (subscription required) (2/11) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  • Early trials may be enough for experimental drugs to get FDA OK
    The FDA granted "breakthrough" status to three promising experimental drugs as part of efforts to speed market entry for treatments of life-threatening conditions. "We expect many of these would come available very quickly with Phase I data," FDA Center for Drug Evaluation and Research Director Janet Woodcock said. Applications for breakthrough status have been made for 18 other treatments, she said. Bloomberg Businessweek (2/12) LinkedInFacebookTwitterEmail this Story
  Advancing Health Care 
  • Agency to award grants for stage 3 MU studies
    The Agency for Healthcare Research and Quality will award grants of as much as $250,000 in support of research designed to assess the implementation of proposed stage 3 meaningful use objectives among health care providers and facilities. The deadline for submission of applications is March 28. Health Data Management (2/12) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
  From SNMMI 
  • Special symposium: Photons Across Medicine -- April 15, 2013
    Join SNMMI for a special symposium on the use of photons across medical imaging, taking place during the Optics in the Life Sciences Congress, April 14-18 in Waikoloa Beach, Hawaii. During this congress, you'll explore the latest advances in molecular probe development, life science imaging, novel and more powerful optical instrumentation and its application to study fundamental biological processes and clinical investigations. Register today. LinkedInFacebookTwitterEmail this Story
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

  SmartQuote 
Several excuses are always less convincing than one."
--Aldous Huxley,
British author


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
   
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Advertise
Account Director:   Meryl Harold   (202) 407-7828
 
Read more at SmartBrief.com
 
 
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.®  Legal Information